FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesNavigating Regulatory and QA Challenges in Clinical Supply Management
Topic: Regulatory
Executive Summary
Members
Brexit & the future landscape for clinical trial supplies in the UK and Europe
Topics: Pharma Industry, Regulatory, Supply Chain
Position Paper
Free
Commercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
